Published in Int J Tuberc Lung Dis on May 01, 2011
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis (2011) 2.72
Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One (2012) 2.53
Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci Transl Med (2012) 1.65
Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV. Int J Tuberc Lung Dis (2014) 1.46
Epidemiology and interaction of diabetes mellitus and tuberculosis and challenges for care: a review. Public Health Action (2013) 1.41
Impact of human immunodeficiency virus and CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South Africa. Int J Tuberc Lung Dis (2013) 1.28
Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2012) 1.26
HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc (2012) 1.21
Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa. J Int AIDS Soc (2012) 1.05
Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy--Mozambique, 2004-2008. PLoS One (2013) 1.02
Mass HIV Treatment and Sex Disparities in Life Expectancy: Demographic Surveillance in Rural South Africa. PLoS Med (2015) 0.97
T cell susceptibility to HIV influences outcome of opportunistic infections. Cell (2013) 0.95
PEPFAR support for the scaling up of collaborative TB/HIV activities. J Acquir Immune Defic Syndr (2012) 0.95
Six-month mortality among HIV-infected adults presenting for antiretroviral therapy with unexplained weight loss, chronic fever or chronic diarrhea in Malawi. PLoS One (2012) 0.93
Association of BMI category change with TB treatment mortality in HIV-positive smear-negative and extrapulmonary TB patients in Myanmar and Zimbabwe. PLoS One (2012) 0.92
Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS One (2012) 0.91
Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis. PLoS One (2013) 0.87
Temporal trends in TB notification rates during ART scale-up in Cape Town: an ecological analysis. J Int AIDS Soc (2015) 0.85
Harnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosis. Curr HIV Res (2011) 0.84
'Getting to Zero': are there grounds for optimism in the global fight against HIV? Indian J Med Res (2012) 0.83
Antiretroviral treatment as prevention: impact of the 'test and treat' strategy on the tuberculosis epidemic. Curr HIV Res (2011) 0.83
Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS (2015) 0.82
Timing of antiretroviral therapy in Cambodian hospital after diagnosis of tuberculosis: impact of revised WHO guidelines. Bull World Health Organ (2012) 0.82
Integrating Community-Based Interventions to Reverse the Convergent TB/HIV Epidemics in Rural South Africa. PLoS One (2015) 0.81
Differences in antigen-specific CD4+ responses to opportunistic infections in HIV infection. Immun Inflamm Dis (2015) 0.80
PD-1 Expression and Cytokine Secretion Profiles of Mycobacterium tuberculosis-Specific CD4+ T-Cell Subsets; Potential Correlates of Containment in HIV-TB Co-Infection. PLoS One (2016) 0.80
Treatment of latent tuberculosis infection in HIV: shorter or longer? Curr HIV/AIDS Rep (2012) 0.80
Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr (2016) 0.80
Incidence of Opportunistic Infections and the Impact of Antiretroviral Therapy Among HIV-Infected Adults in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. Clin Infect Dis (2016) 0.78
Prevalence and correlates of alcohol dependence disorder among TB and HIV infected patients in Zambia. PLoS One (2013) 0.78
High rates of tuberculosis in patients accessing HAART in rural South Africa. J Acquir Immune Defic Syndr (2014) 0.77
Wide Variations in Compliance with Tuberculosis Screening Guidelines and Tuberculosis Incidence between Antiretroviral Therapy Facilities - Côte d'Ivoire. PLoS One (2016) 0.75
Timely HIV diagnosis and HIV/TB comanagement among California patients in 2008. Public Health Rep (2014) 0.75
Implementation of a pragmatic, stepped-wedge cluster randomized trial to evaluate impact of Botswana's Xpert MTB/RIF diagnostic algorithm on TB diagnostic sensitivity and early antiretroviral therapy mortality. BMC Infect Dis (2016) 0.75
Enhancing the impact of antiretroviral scale-up on the HIV-associated tuberculosis epidemic in Malawi. Public Health Action (2014) 0.75
Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy. BMC Infect Dis (2017) 0.75
HIV-1 Infection Is Associated with Depletion and Functional Impairment of Mycobacterium tuberculosis-Specific CD4 T Cells in Individuals with Latent Tuberculosis Infection. J Immunol (2017) 0.75
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med (2003) 24.99
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (2006) 21.60
An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med (1992) 13.29
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet (2007) 9.71
Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med (2010) 8.72
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet (2009) 6.96
Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS (2005) 6.83
Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis (2005) 6.59
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54
The mortality and pathology of HIV infection in a west African city. AIDS (1993) 6.08
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68
Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS (2001) 5.61
Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet (1993) 5.52
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis (2007) 5.40
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev (2010) 4.95
Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet (2010) 4.95
HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med (2009) 4.76
Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS (2007) 4.52
HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet (2001) 4.33
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07
The HIV-associated tuberculosis epidemic--when will we act? Lancet (2010) 3.82
How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis (2004) 3.50
Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet (1998) 3.45
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis (2008) 3.33
Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis (2002) 3.05
Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS (2009) 2.86
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med (2010) 2.86
Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science (2003) 2.83
HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis (2006) 2.82
Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.72
Tuberculosis in Africa--combating an HIV-driven crisis. N Engl J Med (2008) 2.67
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis (2007) 2.51
Rates of tuberculosis transmission to children and adolescents in a community with a high prevalence of HIV infection among adults. Clin Infect Dis (2008) 2.42
Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet (1995) 2.42
Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis (2010) 2.38
How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS (2005) 2.28
Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis (2009) 2.25
Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med (2009) 2.20
Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis (1999) 2.18
Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. PLoS One (2010) 2.12
Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA (1995) 2.08
Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis (2010) 1.92
Tuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis. Microbes Infect (2002) 1.67
Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis (1990) 1.60
Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A (2010) 1.48
Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS (2010) 1.43
Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med (2010) 1.42
Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART. AIDS (2006) 1.40
Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis (2003) 1.36
WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for antiretroviral treatment: relationship to CD4 lymphocyte counts. Int J Tuberc Lung Dis (2005) 1.35
Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2008) 1.34
AIDS-related tuberculosis in Rio de Janeiro, Brazil. PLoS One (2008) 1.21
The impact of the HIV epidemic on tuberculosis transmission in Tanzania. AIDS (2006) 1.20
Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS (1999) 1.12
Tuberculosis-HIV co-infection: policy and epidemiology in 25 countries in the WHO European region. HIV Med (2008) 1.10
Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis (2008) 1.09
Autopsy findings in HIV-1-infected adults in Kenya. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.06
Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Côte d'Ivoire. AIDS (1995) 1.05
Impact of the HIV epidemic on trends in tuberculosis in Abidjan, Côte d'Ivoire. Tuber Lung Dis (1995) 1.03
Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. AIDS (2008) 1.03
Should pulmonary tuberculosis be an AIDS-defining diagnosis in patients infected with HIV? Tuber Lung Dis (1992) 0.88
Charon phages: safer derivatives of bacteriophage lambda for DNA cloning. Science (1977) 20.27
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med (1993) 8.49
AIDS as a zoonosis: scientific and public health implications. Science (2000) 8.28
Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States medicare population. J Bone Joint Surg Am (2001) 7.67
Restriction maps for twenty-one Charon vector phages. J Virol (1980) 7.51
Cancer risks from arsenic in drinking water. Environ Health Perspect (1992) 6.98
Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet (1998) 6.94
Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Trans R Soc Trop Med Hyg (2008) 6.39
HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health (2001) 6.29
The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (2001) 5.89
The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals. Am J Public Health (2001) 5.32
Community support is associated with better antiretroviral treatment outcomes in a resource-limited rural district in Malawi. Trans R Soc Trop Med Hyg (2006) 5.18
Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis (2011) 5.14
Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am J Public Health (1987) 5.06
Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med (1999) 5.05
Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis (2005) 4.36
Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis (1987) 4.11
Non-smoking: a feature of ulcerative colitis. Br Med J (Clin Res Ed) (1982) 4.08
Language in tuberculosis services: can we change to patient-centred terminology and stop the paradigm of blaming the patients? Int J Tuberc Lung Dis (2012) 4.05
Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes--the case of Malawi. Int J Tuberc Lung Dis (2005) 4.04
Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med (1994) 4.04
Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) (1988) 4.03
Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr (2001) 3.67
Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med (1991) 3.64
Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ (2009) 3.62
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis (1992) 3.61
Routine prenatal screening for HIV infection. Lancet (1991) 3.43
Building leadership capacity and future leaders in operational research in low-income countries: why and how? Int J Tuberc Lung Dis (2011) 3.40
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet (1998) 3.37
Accumulation of non-protein metal-binding polypeptides (gamma-glutamyl-cysteinyl)n-glycine in selected cadmium-resistant tomato cells. J Biol Chem (1986) 3.22
Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA (1998) 3.07
Construction and characterization of the hybrid bacteriophage lambda Charon vectors for DNA cloning. J Virol (1979) 2.99
Delayed tuberculosis diagnosis and tuberculosis transmission. Int J Tuberc Lung Dis (2006) 2.97
Passive versus active tuberculosis case finding and isoniazid preventive therapy among household contacts in a rural district of Malawi. Int J Tuberc Lung Dis (2003) 2.89
Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy. Int J Tuberc Lung Dis (2004) 2.81
Expansion of surveillance case definition for AIDS in resource-poor countries. Lancet (1993) 2.80
Applying the ICMJE authorship criteria to operational research in low-income countries: the need to engage programme managers and policy makers. Trop Med Int Health (2013) 2.78
Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis (2011) 2.77
Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med (1991) 2.77
An association between HIV-1 subtypes and mode of transmission in Cape Town, South Africa. AIDS (1997) 2.74
Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS (1999) 2.73
The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA (1998) 2.69
Counselling, HIV testing and adjunctive cotrimoxazole for TB patients in Malawi: from research to routine implementation. Int J Tuberc Lung Dis (2004) 2.67
Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses (2004) 2.64
Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis (2010) 2.60
Why is mortality higher in Scotland than in England and Wales? Decreasing influence of socioeconomic deprivation between 1981 and 2001 supports the existence of a 'Scottish Effect'. J Public Health (Oxf) (2005) 2.58
Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis (2008) 2.55
Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother (1999) 2.54
Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis (2001) 2.51
Biological activity of paramyxovirus fusion proteins: factors influencing formation of syncytia. J Virol (1992) 2.47
Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med (2001) 2.47
Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci U S A (2000) 2.46
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med (1991) 2.46
Earlier HIV diagnosis--are mobile services the answer? S Afr Med J (2010) 2.46
Errors in the treatment of tuberculosis in Baltimore. Chest (2000) 2.46
Projections of AIDS morbidity and mortality in San Francisco. JAMA (1990) 2.42
Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet (1995) 2.42
Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis (2005) 2.40
Multigenic drug resistance among inbred malaria parasites. Proc Biol Sci (1997) 2.34
Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J (Clin Res Ed) (1982) 2.32
Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 2.29
Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death. Trans R Soc Trop Med Hyg (2002) 2.27
Eleven years of community-based directly observed therapy for tuberculosis. JAMA (1995) 2.27
Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA (2000) 2.25
Monitoring trends in under-5 mortality rates through national birth history surveys. Int J Epidemiol (2004) 2.21
Does antiretroviral treatment reduce case fatality among HIV-positive patients with tuberculosis in Malawi? Int J Tuberc Lung Dis (2007) 2.21
Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis (1999) 2.18
Latent tuberculosis infection among undergraduate medical students in Rio de Janeiro State, Brazil. Int J Tuberc Lung Dis (2005) 2.16
Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis (2011) 2.15
Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med (1996) 2.14
Insertion of DNA carrying ribosomal protein genes of Escherichia coli into Charon vector phages. J Biol Chem (1977) 2.13
Reduced tuberculosis case notification associated with scaling up antiretroviral treatment in rural Malawi. Int J Tuberc Lung Dis (2011) 2.13
Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med (1991) 2.12
Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire. Lancet (1997) 2.12
Dissection and comparative anatomy of the origins of replication of lambdoid phages. Cold Spring Harb Symp Quant Biol (1979) 2.11
Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group. JAMA (1991) 2.08
Tuberculosis control in South Africa--time for a new paradigm? S Afr Med J (1996) 2.08
Provider-initiated HIV testing and counselling for TB patients and suspects in Nairobi, Kenya. Int J Tuberc Lung Dis (2008) 2.05
Incidence of salmonellosis in patients with AIDS. J Infect Dis (1987) 2.04
Mycobacteria and AIDS mortality. Am Rev Respir Dis (1989) 2.02
Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis (2000) 2.02
Teenage mothers and the health of their children. Popul Trends (1998) 2.01
Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis (1995) 2.01
Care seeking behaviour and diagnostic processes in patients with smear-positive pulmonary tuberculosis in Malawi. Int J Tuberc Lung Dis (2000) 1.99
Tuberculosis in a prison population in Malawi. Lancet (1997) 1.98
How can the community contribute in the fight against HIV/AIDS and tuberculosis? An example from a rural district in Malawi. Trans R Soc Trop Med Hyg (2005) 1.97
Presurgical columellar elongation and primary retrograde nasal reconstruction in one-stage bilateral cleft lip and nose repair. Plast Reconstr Surg (1998) 1.97
Cryptosporidiosis in patients with AIDS: correlates of disease and survival. Clin Infect Dis (1998) 1.97
Disease in children infected with HIV in Abidjan, Côte d'Ivoire. BMJ (1996) 1.92
Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis (2009) 1.92
Pneumocystis carinii pneumonia. An uncommon cause of death in African patients with acquired immunodeficiency syndrome. Am Rev Respir Dis (1992) 1.92
'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence. Int J Tuberc Lung Dis (2001) 1.92
Back pain in young athletes. Significant differences from adults in causes and patterns. Arch Pediatr Adolesc Med (1995) 1.91
Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis (2006) 1.91